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ABSTRACT: NR2E3, a photoreceptor-specific nuclear
receptor (PNR), represses cone-specific genes and
activates several rod-specific genes. In humans, muta-
tions in NR2E3 have been associated with the reces-
sively-inherited enhanced short-wavelength sensitive S-
cone syndrome (ESCS) and, recently, with autosomal
dominant (ad) retinitis pigmentosa (RP) (adRP). In the
present work, we describe two additional families affected
by adRP that carry a heterozygous c.166G4A (p.G56R)
mutation in the NR2E3 gene. Functional analysis
determined the dominant negative activity of the
p.G56R mutant protein as the molecular mechanism of
adRP. Interestingly, in one pedigree, the most common
causal variant for ESCS (p.R311Q) cosegregated with the
adRP-linked p.G56R mutation, and the compound
heterozygotes exhibited an ESCS-like phenotype, which
in 1 of the 2 cases was strikingly ‘‘milder’’ than the
patients carrying the p.G56R mutation alone. Impaired
repression of cone-specific genes by the corepressors
atrophin-1 (dentatorubral-pallidoluysian atrophy
[DRPLA] gene product) and atrophin-2 (arginine-
glutamic acid dipeptide repeat [RERE] protein) appeared
to be a molecular mechanism mediating the beneficial
effect of the p.R311Q mutation. Finally, the functional
dominance of the p.R311Q variant to the p.G56R
mutation is discussed.
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Introduction
NR2E3 (MIM] 604485), also called photoreceptor-specific
nuclear receptor (PNR), is a photoreceptor-specific transcription
factor of the nuclear hormone receptor superfamily [Kobayashi
et al., 1999]. NR2E3 exhibits the evolutionary-conserved modular
structure of nuclear receptors, namely a highly-conserved DNA-
binding domain (DBD) that specifically binds to consensus
binding sites located in promoters of target genes, and a ligand-
binding domain (LBD) [Chen et al., 2005; Kobayashi et al., 1999].
Although NR2E3 acts as a transcriptional activator of several rod-
specific genes, in synergy with the cone-rod homeobox (CRX;
MIM] 602225) and the neural retina leucine zipper (NRL; MIM]
162080) transcription factors [Cheng et al., 2004, 2006; Peng et al.,
2005], a physiological function of NR2E3 is thought to be
repression of cone-specific genes in rods [Chen et al., 2005; Peng
et al., 2005]. For instance, transgenic mice ectopically expressing
NR2E3 under the control of the CRX promoter in photoreceptor
precursor cells showed a suppression of cone-specific gene
expression; consequently, differentiation of cone photoreceptor
cells was suppressed, but nonfunctional rod-like photoreceptor
cells were generated [Cheng et al., 2006]. The critical role of
NR2E3 for the regulation of photoreceptor generation became
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evident in the rd7/rd7 mice, a spontaneous loss-of-function model
of NR2E3 [Akhmedov et al., 2000; Haider et al., 2001]. In rd7/rd7
retinas, blue (S-cone) opsin expressing cone cells are generated
throughout postnatal life. This abnormal number of cones leads to
laminar disorganization and fragmentation of the retina [Akhme-
dov et al., 2000; Haider et al., 2001, 2006]. NR2E3 might therefore
be needed to suppress the cone generation program in late mitotic
retinal progenitor cells [Haider et al., 2006].
In humans, mutations in NR2E3 have been associated with the
recessively-inherited enhanced short-wavelength sensitive S-cone
syndrome (ESCS; MIM] 268100) [Haider et al., 2000]. ESCS is
characterized by unique full-field and spectral electroretinographic
findings with hyperfunction of S-cones (‘‘blue’’ cones) and
impaired M-cone, L-cone, and rod functions [Gouras, 1981;
Gouras et al., 1985; Jacobson et al., 1990; Marmor et al., 1990]. To
date, 20 different mutations located in the evolutionary-conserved
DBD and LBD of NR2E3 have been linked to ESCS, with
c.932G4A (p.R311Q) being the most prevalent [Haider et al.,
2000; Hayashi et al., 2005; Milam et al., 2002; Sharon et al., 2003;
Wright et al., 2004].
Recently, a c.166G4A (p.G56R) mutation in the NR2E3 gene
was reported as being one of the more common single causal
mutations for autosomal-dominant (ad) retinitis pigmentosa (RP)
(adRP), termed RP37 (MIM] 611131) [Coppieters et al., 2007;
Gire et al., 2007]. The phenotype corresponded to that seen in
classic adRP, with progressive degeneration of rods and subse-
quent involvement of cones.
In the present work, we functionally characterized the p.G56R
mutation that we had previously identified [Bouayed-Tiab et al.,
2006], and showed that dominant negative activity of the mutant
protein was the molecular mechanism underlying adRP. We also
analyzed a pedigree in which adRP and ESCS segregate due to the
presence of a p.G56R/wild-type or a p.G56R/p.R311Q genotype.
We addressed the mechanisms by which the recessive trans-acting
p.R311Q (ESCS) mutation has a protective effect when uncovered
by the dominant cis-acting p.G56R (adRP) mutation. Additionally,
we identified atrophin-1, the dentatorubral-pallidoluysian atrophy
(DRPLA) gene product [Yazawa et al., 1995], and the related
atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein
[Yanagisawa et al., 2000] as corepressors of NR2E3 and showed that
impaired corepressor activity may be the molecular basis of ESCS.
Materials and Methods
Patient Information and Examination
Studies were conducted under protocols approved by the
Institutional Review Boards of Hoˆpital Ophtalmique Jules-Gonin
for the Swiss family and of Columbia University for the American
family of Jewish origin. Written informed consent for clinical
examination and DNA analysis was obtained from all individuals.
Each patient and several unaffected family members were
examined by standard ophthalmological methods, including
fundus photography and electroretinography (ERG); the older
subjects were examined over a 25-year period.
To determine dark-adapted thresholds, a Goldmann-Weekers
adaptometer (Haag-Streit, Bern, Switzerland) was used. Since only
the final dark-adapted threshold, and not dark adaptation curves,
was being determined, a preadapting light was unnecessary. Final
dark-adapted thresholds were obtained in units of luminance
(footlamberts) and were compared to values of normal controls
on the same adaptometer. Color vision was normal in all subjects
on the Farnsworth Panel D-15.
For ERG measurements, the light source was a Grass stimulator
recessed in a ganzfeld dome. The subjects were first studied in
the dark-adapted state using spectral stimuli obtained by the use
of four Kodak Wratten filters (29 [red], 21 [yellow], 61 [green],
and 98 [blue](Eastman Kodak Company, Rochester, NY)).
Then the subjects were light-adapted with a steady ganzfeld
background of 53 footlamberts and the responses to the four
spectral stimuli were obtained again (Supplementary Fig. S1A;
available online at http://www.interscience.wiley.com/jpages/1059-
7794/suppmat). A complete description of this methodology has
been published [Gouras et al., 1985]. In addition, ERG responses
were obtained to white light stimulation. Responses were detected
at the cornea by Burian-Allen bipolar contact lens electrodes and
amplified by a Nicolet computer system with low noise amplifiers,
averaging usually 50 to 100 responses to the same flash presented
every second (Alden Products Company, Brockton, MA). In one
case (proband Patient II-1) a spectral sensitivity function for the
ERG was obtained in the dark- and light-adapted state by defining
the relationship between ERG amplitude and the energy of
stimulation using four additional Wratten filters and then
determining the energy required for each filter to produce a
constant slightly suprathreshold response in the dark- and light-
adapted state (Supplementary Fig. S1B).
Reagents
If not stated otherwise, chemical reagents were from Fluka-
Sigma (Buchs, Switzerland); oligonucleotides from Eurogentec
(Lie`ge, Belgium) and Microsynth (Balgach, Switzerland); DNA
purification kits from Macherey-Nagel (Du¨ren, Germany);
plasticware from Techno Plastic Products (Trasadingen, Switzer-
land); and cell culture reagents from Invitrogen (Paisley, UK).
Genotyping, Linkage Analysis, and Mutation Detection
Blood samples were obtained for DNA analysis from 11 out of
13 affected and 16 out of 18 nonaffected members of the Swiss
family and all members of the American family. DNA was isolated
from leukocytes (Nucleon Bacc2; Amersham Biosciences, Otelfin-
gen, Switzerland). As inheritance was clearly dominant in the
Swiss family, linkage analysis was performed in a two-step
approach. First, two markers flanking each of the 15 most
frequent adRP loci (CA4, CRX, FSCN2, GUCA1B, IMPDH1,
NRL, PRPF3, PRPF8, PRPF31, RDS, RHO, ROM1, RP1, RP9, and
SEMA4) were chosen and haplotypes were established. Second,
because all loci were excluded, a genome-wide linkage analysis was
performed with 380 microsatellites from the ABI linkage mapping
set 2.5 (average distance between markers: 10 cM). Haplotypes
were determined with Autoscan V1.01B and logarithm of
odds (lod) scores were calculated using Mlink V5.1 under the
assumption of autosomal dominant inheritance with complete
penetrance, a neomutation rate of 0.001, and equal allele
frequency (http://www.genetics.ucla.edu/software/autoscan).
Heteroduplex analysis of NR2E3 amplicons was performed
using an automated denaturing high-performance liquid chro-
matography (DHPLC) instrument (WAVE; Transgenomic,
Glasgow, UK). Amplicons with abnormal retention time were
directly sequenced on an ABI 3100XL DNA sequencer (Applied
Biosystems [ABI], Foster City, CA) using a Big Dye Terminator
Labeling Kit (ABI). Finally, after identification of the p.G56R
mutation, the potential promoter region, exonic, and intronic
sequences of the NR2E3 gene were directly sequenced for all
patients after PCR amplification.
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NR2E3 cDNA Mutagenesis
The cDNA bases were numbered according to the human
NR2E3 reference sequence in GenBank NM_014249.2, where 11
corresponds to the A of the ATG translation initiation codon.
Mutagenesis was performed according to the QuikChangesII
Site-Directed Mutagenesis Kit using PfuUltra polymerase (Strata-
gene, Cedar Creek, TX). Briefly, pcDNA3.1/HisC-hNR2E3 [Peng
et al., 2005] was amplified with forward 50-GTGCGGAGACAGC
AGCAGCAGGAAGCACTATGGC-30 and reverse 50-GCCATAGTG
CTTCCTGCTGCTGCTGTCTCCGCAC-30 oligonucleotides to ob-
tain the pcDNA3.1/HisC-hNR2E3-G56R plasmid. To obtain the
pcDNA3.1/HisC-hNR2E3R311Q plasmid, oligonucleotides 50-CC
TGCAGGAAACTATCTCTCGGTTCCAGGCATTGGCGG-30 and
50-CCGCCAATGCCTGGAACCGAGAGATAGTTTCCTGCAGG-30
were used.
Transactivation Assays
A mouse S-opsin promoter fragment (opn1sw) spanning
nucleotides 736/117 relative to the ATG was amplified with
oligonucleotides 50-GGGGTACCGGTGTGATGATGCTGACAAG-30
and 50-CGGGATCCTCATCCTCTC CTGACATCTC-30, verified by
sequencing, and then subcloned into KpnI/BglII sites of the pGL2-
promoter luciferase reporter vector (Promega, Madison, WI).
Human embryonic kidney (HEK) 293T cells were grown
in DMEM containing 10% FCS and penicillin/streptomycin
(Invitrogen). Cells were plated in 12-well plates and transfected
at a confluence of 30% with the calcium phosphate method
(ProFections; Promega). Per well, 30 ng of each of the expression
vectors pcDNA3.1/HisC-hNR2E3 (wild-type, p.R311Q, and
p.G56R), pcDNA3.1/HisC-hCRX, and pMT-NRL were used
[Peng et al., 2005], together with 500 ng of the luciferase
reporter constructs for rhodopsin promoter BR225-Luc [Peng
et al., 2005], for M-opsin promoter Mop250-Luc [Peng et al.,
2005], or for the S-opsin promoter (see above). As internal
standard, 50 ng of plasmid CMVb (Clontech, Mountain View,
CA) encoding b-galactosidase was used. For corepressor studies,
33, 66, or 100 ng of the pCMX expression vectors encoding
FLAG-tagged atrophin-1, atrophin-2, and nuclear receptor
corepressor (NCoR) were transfected [Ho¨rlein et al., 1995; Wang
et al., 2006]. To keep the total transfected DNA quantity constant,
appropriate quantities of pcDNA3.1/HisC and pCMX-FLAG
empty vectors were added in all experiments. Enzymatic activities
were assessed with the Luciferase Assay System (Promega) and
standard b-Gal assay. For corepressor studies, we considered only
experiments where the b-galactosidase activities were comparable
between all wells.
Electrophoretic Mobility Shift Assay (EMSA)
The pcDNA3.1/HisC-hNR2E3 expression vectors were used for
in vitro transcription/translation (TNT; Promega). In vitro DNA-
binding was tested on the annealed oligonucleotides NR2E3REfor
(50-CCTTTAAAAGTCAAAAGTCAACTTCCAA-30) and NR2E3R-
Erev (50-TTCCGTTGGAAGTTGACTTTTGACTTTT-30). Radiola-
beling by Klenow fill-in with 30 mCi of [a-32P]dATP (3,000 Ci/
mmol) (Hartmann Analytik, Braunschweig, Germany) and
subsequent probe purification on Sephadex G-50 columns
(Roche, Basel, Switzerland) was according to the manufacturer’s
instructions. DNA-binding reactions were carried out in 20 ml of
10mM Tris (pH 7.5), 160mM KCl, 1mM DTT, 10% glycerol,
10 mg of sonicated salmon sperm DNA (Roche), and 2 mg of
poly(dI-dC) with indicated amounts of programmed reticulocyte
lysate. For competition experiments, unlabeled probes were added
in 2- to 100-fold molar excess. After a 15-min incubation on ice,
1 ng of 32P-labeled probe was added, and incubations were
continued for an additional 15min at room temperature. For
‘‘supershift’’ experiments, 2 mg of rabbit polyclonal anti-human
NR2E3 (1 mg/ml; Millipore, Billerica, MA) was added to the
reaction and incubation proceeded for another 10min. DNA-
protein complexes were separated from free probe on native 4%
polyacrylamide gel in 0.5 Tris/borate/EDTA (TBE) buffer, gels
were dried and revealed by phosphorimaging (GE Healthcare,
Piscataway, NJ).
Animal Handling
All experiments performed in this study were in accordance
with the Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Vision Research and were approved by the Veterinary Service of
the State of Valais (Switzerland). C57BL/6 mice (RCC, Basel,
Switzerland) were kept in a 12-hr light-dark cycle with unlimited
access to food and water.
Chromatin-Immunoprecipitations
Experiments were carried out on six retinas exactly as described
[Peng and Chen, 2005], except protein-protein cross-linking of
cells in 1.5mM ethylene glycolbis[succinimidyl succinate] (EGS)
preceded formaldehyde fixation [Zeng et al., 2006]. For im-
munoprecipitation, a sheep polyclonal anti-atrophin-1 (A-19)
antibody was used (Santa Cruz Biotechnology, Santa Cruz, CA).
In Situ Hybridization
Eyes were enucleated, rinsed in 1PBS–DEPC, fixed for 2 hr
with 4% paraformaldehyde1PBS-DEPC and included for
overnight in 30% sucrose-1PBS-DEPC. Eyes were sectioned at
211C on a Leica CM1900 cryostat (Leica Microsystems,
Heerbrugg, Switzerland) and 12-mm sections recovered on
SuperFrostsPlus microscope slides (Menzel Gla¨ser, Braunschweig,
Germany) pretreated with Vectabond (Vector Laboratories,
Burlingame, CA). A 250 bp-probe for atrophin-1 was amplified
from reverse-transcribed mouse brain mRNA with primers 50-
CTTCGTCACCAGCTTTTTGC-30 and 50-GCTTGTCACTCTCC
TTCTTC-30, and then subcloned into the pGEMs-T Easy vector
(Promega). DIG-labeled sense and antisense probes were tested by
immunodot blotting. In situ hybridizations were carried out at
481C as previously described [Braissant and Wahli, 1998].
Results
Mutations in NR2E3 Cause Dominant or Recessive Retinal
Diseases
During our systematic screening of families with various forms
of RP in Switzerland, we identified a large family in which 11
members were affected with classical autosomal dominant RP
(Fig. 1A). In this family, a genome-wide linkage analysis had
resulted in a strong positive lod score of 4.08 for marker D15S205
(Fig. 1C). Haplotype analysis restricted the shared interval to
markers D15S153 and D15S127 (data not shown). As this interval
contained the NR2E3 gene, the putative promoter, exons and
introns of NR2E3 were directly sequenced and the causal mutation
for adRP37 (MIM] 611131), c.166G4A (p.G56R), was identified
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in all affected individuals. None of the nonaffected family
members possessed this variant nor was it found in more than
200 ethnically-matched control individuals. The patients of the
Swiss family did not possess any other NR2E3 variants.
We have followed an American family since 1980, with evidence
of retinal degeneration in two generations (Fig. 1B) [Gouras,
1981]. Two affected grandchildren in the third generation were
included over time. The proband, Patient II-1, had a most unusual
ERG that showed supernormal responses to short wavelength
stimuli [Gouras et al., 1985], which subsequently became known
as the enhanced S-cone syndrome (ESCS) [Jacobson et al., 1990;
Marmor et al., 1990] (Fig. 2G; Supplementary Fig. S1). The
proband had had night blindness since childhood but, remarkably,
had no evidence of RP at 65 years of age with full visual fields (Fig.
2A and B; Table 1). Indeed, a dominant form of RP characterized
by retinal pigmentary changes, visual field defects, night blindness,
and a profound reduction in the ERG, was present in her son
(Patient III-2) and her two grandchildren (Patients IV-1 and IV-2)
(Fig. 2E–G; Table 1). The parents, Patients I.1 and I.2, were long
deceased, but there was anecdotal evidence that the mother
(Patient I.2) and her sister had vision problems, the latter being
blind at an elderly age. The proband’s sister (Patient II-3) had
attenuated retinal vessels and massive clumped intraretinal
pigmentation in her midperipheral retina (Fig. 2C and D).
However, an electrophysiological finding suggested a more ESCS-
like than adRP-like phenotype. Her response to blue light had
greater amplitude than that of her nephew’s (Patient III-2),
whereas the converse was the case for red light (Fig. 2G). Her
dark-adapted threshold to peripheral testing was lower than that
of her younger nephew’s (Table 1) and her visual fields in the
1980 s were larger than her nephew (Patient III-1). The field of
Patient II-3 extended slightly beyond 20 degrees of visual angle
while that of her much younger nephew extended to only 10
degrees in the 1980 s. Now their visual fields are less than 5
degrees. Therefore, both Patient II-3 and Patient III-1 progressed
with time but they had different phenotypes. Patient II-3 had
more peripheral field function and a more ESCS-like ERG than
her younger nephew. Both Patient II-1 and Patient II-3 had
evidence of foveal dysfunction, as demonstrated by their slightly
reduced acuities (Table 1), which has declined very slowly since
1980. The other affected members of the pedigree have retained
normal visual acuity.
Importantly, the proband, Patient II-1, and her sister, Patient II-
3, were determined to be compound heterozygotes for two NR2E3
mutations: the most common causal mutation for ESCS p.R311Q
[Haider et al., 2000]; and the causal mutation for adRP p.G56R
(Fig. 1B). Her son (Patient III-2) and both grandchildren (Patients
IV-1 and IV-2), who were all affected by adRP, had solely inherited
the p.G56R mutation from their mother/grandmother and did not
possess any other NR2E3 variants.
On the basis of these different clinical and genetic data, we
therefore aimed at elucidating: 1) the molecular mechanisms
leading to p.G56R-linked adRP; and 2) the molecular mechanisms
underlying the ESCS-like phenotype in the two p.G56R/p.R311Q
compound heterozygous patients.
The NR2E3-G56R Mutant Acts as a Dominant Negative
Protein
Glycine 56 is located in the highly-conserved DBD of NR2E3 at
the base of the a-helical DNA-binding motif of the first so-called
‘‘zinc-finger’’-like structure (Fig. 3). To test whether the p.G56R
mutation abolished DNA binding by disrupting the a-helical
DNA-binding motif, we performed EMSAs with in vitro translated
NR2E3 wild-type and mutant proteins on a synthetic NR2E3
response element that consisted of a direct repeat of two NR2E3
consensus binding sites spaced by one nucleotide (Fig. 4). We
observed, in the presence of the NR2E3 wild-type protein, a
specific complex that had been suggested to be a NR2E3
homodimer (Fig. 4A, lane 2) [Kobayashi et al., 1999]. The
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Figure 1. Pedigrees of affected families of Swiss (A) and Jewish-American (B) origin. All patients with black symbols harbor the G56R
heterozygous mutation and are affected with adRP, while the two patients with dark gray symbols are compound heterozygous G56R/R311Q and
are affected with ESCS syndrome. Individuals with the heterozygous R311Q mutation (light gray symbols) have no clinical phenotype. Arrow
denotes the proband of the American family. C: Lod scores for microsatellite markers obtained in the Swiss family.
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specificity of binding was demonstrated by specific competition
with increasing amounts of unlabeled oligonucleotides (Fig. 4A,
lanes 4–7) and by nonspecific competition with an unrelated
response element for Ets transcription factors (Fig. 4A, lane 3).
Further evidence of specificity was provided by the binding of
anti-NR2E3 antisera to the NR2E3 complex, resulting in a slower
migrating complex, appearing as a smear in the uppermost part of
the lane (Fig. 4A, lane 8). In contrast to the NR2E3 wild-type
protein, no complex was observed in presence of an equivalent
amount of the p.G56R protein, indicating that the mutant protein
was unable to bind DNA (Fig. 4A, lanes 9–13). Similar to NR2E3
wild-type protein, the p.R311Q protein bound the NR2E3
response element as a specific complex (Fig. 4A, lanes 14–18).
We observed a strong signal corresponding to the NR2E3 dimer in
presence of both NR2E3 wild-type and p.R311Q proteins (Fig. 4A,
lane 19), suggesting that the p.R311Q mutation located in the
LBD did not impair dimerization with wild-type NR2E3.
Increasing amounts of the p.G56R protein abolished binding of
both NR2E3 wild-type and p.R311Q proteins (Fig. 4B, lanes 1–6).
By decreasing the amount of p.R311Q proteins and increasing
those of p.G56R, dimer binding to the radiolabeled probe became
gradually weaker. Notably, in the presence of equivalent amounts
of the two NR2E3 mutant proteins, which is potentially
mimicking the situation in the heterozygous patients, binding of
dimers to DNA was barely detected (Fig. 4B, lanes 7–11). Taken
together, this suggested that the p.G56R mutant protein was
competent in dimerization, but had a dominant negative effect
toward both NR2E3 wild-type and p.R311Q proteins through its
inability to bind DNA.
We further tested the p.G56R mutant protein in 293T cells,
using luciferase reporter constructs for opsin promoter fragments
(Fig. 5). NR2E3 enhanced CRX/NRL-mediated transactivation of
the rhodopsin promoter in these heterologous transactivation
assays [Peng et al., 2005]. The p.G56R mutant protein did show
Figure 2. Clinical data for the American family. A–F: Fundus photographs. A,B: The proband, Patient II-1, shows a few small spots of clumped
pigmentation in her peripheral retina, mild atrophic changes of the retinal epithelium in the macula, but no attenuation of retinal vessels. C,D:
Her sister, Patient II-3, shows attenuated retinal vessels and clumped intraretinal pigmentation in her midperipheral retina. Patients IV-1 (E) and
IV-2 (F) show a retinal pigmentary clump (arrow) in the peripheral retina. G: ERGs of patients in the American family. The subjects were studied
in the dark-adapted state using Wratten filters providing red (Wratten 29), yellow (Wratten 21), green (Wratten 61) and blue (Wratten 98) light
(see Materials and Methods). The proband, her son, and her sister were analyzed in 1980, when the two most severely affected individuals had
detectable responses. The proband, who is the oldest of all affected, has much better responses than her sister, Patient II-3, and her son,
Patient III-2. Patient II-3’s response to blue light has greater amplitude than that of Patient III-2 (arrows). The converse is true for red light
(arrows). The calibration, lower right, indicates 7 mV vertically and 20ms horizontally.
Table 1. Clinical Features of Patients in the American Family
1980 2003
Dark-adapted
threshold
Dark-adapted
threshold Acuity Visual field
Patient
Age in 1980
(years)
Age in 2003
(years) Central (Ft.L) Peripheral (Ft.L) Central (Ft.L) OD OS OU
II-1 39 62 4 103 4 103 3 103 20/40 20/50 Full
II-3 33 56 7 103 7 102 Difficult 20/50 20/50 Constricted
III-2 18 37 7 103 8 102 Difficult 20/20 20/20 Constricted
IV-1 – 13 – – 4 104 20/20 20/20 Ring scotoma
IV-2 – 10 – – 3 104 20/20 20/20 Ring scotoma
Normal values – – 2–8 106 1–5 106 2–8 106 20/20 20/20 Full
Dark-adapted thresholds (luminance units5 footlamberts5 Ft.L) were determined with a Goldmann-Weekers adaptometer (see Materials and Methods). All patients had
normal color vision. The proband, Patient II-1, and her sister, Patient II-3, presented with macular scotomas. The proband’s grandchildren, Patients IV-1 and IV-2, presented
with ring scotomas.
OD (Latin oculus dexter), right eye; OS (Latin oculus sinister), left eye; OU (Latin oculi uterque), both eyes.
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dominant negative activity, by abolishing NR2E3-driven potentia-
tion of rhodopsin promoter transactivation, in the presence of
either NR2E3 wild-type or p.R311Q proteins. In contrast to the
transactivation of the rhodopsin promoter, NR2E3 repressed S-
and M-opsin promoter activity in HEK293 cell-based assays [Peng
et al., 2005]. Surprisingly, the p.G56R mutant further enhanced
the transrepression of S- and M-opsin promoters, in the presence
of either wild-type or p.R311Q proteins. Importantly, there was
no difference in transactivation levels of all tested opsin
promoters, whether the p.G56R protein was expressed at amounts
equal to the wild-type or to the p.R311Q protein, i.e., potentially
mimicking NR2E3 expression of patients with genotype p.G56R/
wild-type or p.G56R/p.R311Q.
Taken together, these experiments showed that dominant
negative activity, i.e., competition for dimerization by a DNA
binding-defective mutant, was a molecular mechanism intrinsic to
the adRP-linked p.G56R mutant protein, but that this mechanism
could not account for the clinical differences observed in patients
with genotype p.G56R/p.R311Q affected by ESCS-like degeneration
vs. patients with genotype p.G56R/wild-type affected by adRP.
Atrophins Are Corepressors of NR2E3
With the aim of elucidating the effect of the p.R311Q mutation
in the proband, Patient II-1, of the American family and her sister,
Patient II-3 (Fig. 1B), we analyzed the effect of this second
mutation in more detail. Arginine 311 is located in helix 7 of the
NR2E3 LBD (Fig. 3B). This region participates in the binding of
specific ligands to nuclear receptors [Li et al., 2005]. Ligand
binding, in turn, regulates cofactor recruitment on nuclear
receptors [Nettles and Greene, 2005]. As NR2E3 represses cone-
specific genes in rod photoreceptors [Chen et al., 2005; Cheng
et al., 2006; Peng et al., 2005], we hypothesized that the p.R311Q
mutation might alter the binding to corepressors. The recent
description of atrophins as corepressors of NR2E1 [Wang et al.,
2006; Zhang et al., 2006], and the high amino acid sequence
homology between NR2E1 and NR2E3 (Fig. 3C), prompted us to
test atrophins in 293T cell-based transactivation assays for
repressor activity on NR2E3 (Fig. 6A). Atrophins enhanced the
NR2E3-mediated repression on the M-opsin promoter by over
30% when expressed in two-fold excess and by over 50% when
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Figure 3. NR2E3 protein structure. A: The NR2E3 DNA-binding domain (DBD) folds into two ‘‘zinc finger’’-like structures. In the zinc fingers,
the a-helical DNA binding motifs lie perpendicular to each other; one a-helix in each zinc finger, labeled HZnf1 and HZnf2. The p.G56R mutation
is located at the basis of the a-helix of the first zinc finger. B: The NR2E3 ligand-binding domain (LBD) presents a canonical a-helical structure
forming a hydrophobic ligand-binding pocket. R311 is located at the end of helix 7 (H7). Modeling of the mutant protein suggests a slight
destabilization of the a-helical turn immediately C-terminal of R311 (orange dots). Ligand-binding involves residues of H7, but is mainly mediated
by H3, H6, and HAF (AF-2: Activator Function-2). The dimerization interface is mainly located in H9 and H10. Modeling was performed with
SWISSMODEL [Schwede et al., 2003]. C: Human (hs) NR2E1 and NR2E3 amino acid sequences were aligned with the ClustalW 1.83 algorithm
[Chenna et al., 2003]. A/B: N-terminal A/B domain; C: DBD; D: hinge region; E/F: LBD. Identical amino acids are denoted by arrows, conserved
amino acids by dots. In the DBD, the two zinc fingers are indicated by dotted lines. In the LBD, a-helices (H) and b-sheets (s) are indicated by
black boxes. A bold line underlines the C-terminal part of the NR2E1 LBD sufficient for NR2E1/atrophin-1 interaction [Wang et al., 2006; Zhang
et al., 2006]. The sites of p.G56R and p.R311Q mutations are indicated by red letters in the NR2E3 sequence.
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present in three-fold excess. In contrast, NCoR, a reported
corepressor for class I nuclear hormone receptors [Ho¨rlein et al.,
1995], did not enhance M-opsin repression. By in situ hybridiza-
tion experiments, atrophin-1 was detected throughout the retina,
with the highest levels in ganglion cells, at the inner limit of the
inner nuclear layer where the amacrine cells are preferentially
located, and in the inner segments of the photoreceptors (Fig. 6B).
In contrast, atrophin-2 mRNA was not detected in photoreceptors
(data not shown). Consistent with a role in the repression of cone-
specific genes, atrophin-1 was associated with the proximal M-
opsin promoter, as tested by chromatin-immunoprecipita-
tions in adult mouse retinas (Fig. 6C). Expression of atrophin-1
in photoreceptors where NR2E3 is expressed, and association of
atrophin-1 to a NR2E3-regulated promoter in vivo, suggested that
atrophin-1 was a physiologically relevant corepressor of NR2E3.
The NR2E3-R311Q Mutant Is Defective in Atrophin-
Dependent M-Opsin Repression
To test our hypothesis that NR2E3 wild-type and
p.R311Q proteins differentially interacted with corepressors, we
performed transactivation assays in 293T cells (Fig. 6A). When
present in a three-fold excess, atrophin-1 repressed the M-opsin
promoter by over 50% in the presence of wild-type NR2E3
protein, but failed to repress the M-opsin promoter
in the presence of the NR2E3-R311Q protein (P5 0.009). The
same was observed to a lesser extent with atrophin-2 (P5 0.047).
Consistent with a specific binding of atrophins to NR2E3, no
difference in M-opsin repression between NR2E3 wild-type and
p.R311Q proteins was observed in the presence of NCoR. These
results suggested that impaired corepressor binding is the
molecular basis of ESCS.
Discussion
The aims of the present work were as follows: 1) to characterize
the p.G56R mutation causing adRP; and 2) to elucidate
why the presence of two mutations in the compound hetero-
zygotes (p.G56R/p.R311Q) resulted in an ESCS-like
phenotype and in 1 of the 2 cases a much milder phenotype,
whereas the presence of the p.G56R mutation alone resulted in
rapidly progressing adRP.
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Dominant Negative Activity of the adRP-Causing NR2E3-
p.G56R Mutant Protein
We have reported two new families affected by adRP caused by
the p.G56R mutation in the NR2E3 gene. This mutation is unique
among the reported causal NR2E3 mutations, because it acts in a
dominant manner and is located in the first Zn-finger of the DBD.
Indeed, the majority of ESCS patients carry mutations in the LBD.
The few ESCS patients with mutations in the DBD are either
homozygous (G88V, R97H) or compound heterozygous for the
common intron 1 splice-acceptor mutation (IVS1–2A4C) and
R76Q, R76W, R104W or deletion p.65–67 [Haider et al., 2000;
Wright et al., 2004]. This latter mutation deletes the P-box located
at the C-terminus of the first zinc finger, whereas the other
mutations are located in the second zinc finger or in the C-
terminal extension of the DBD. Whether these ESCS-linked
mutations affect DNA-binding and/or dimerization needs to be
determined.
Our functional data showed that the absence of DNA-binding,
but competition for dimer formation, explained the dominant
negative activity exhibited by the p.G56R mutant protein. This
provided a molecular basis for the adRP observed in the patients.
Indeed, if the mutant protein had failed to dimerize, the NR2E3
wild-type protein transcribed from the healthy allele in hetero-
zygous individuals might have been sufficient to maintain normal
NR2E3 activity.
The cell-based transactivation studies were useful to function-
ally characterize the dominant negative activity of the p.G56R
mutant protein, but physiological interpretation of these data
should be done with caution. On the one hand, the modest
decrease by less than 50% in rhodopsin promoter transactivation
by transfecting equivalent amounts of NR2E3 wild-type and
p.G56R proteins, i.e., the ratio one might expect to occur in
heterozygous adRP patients, could be significant in vivo. Indeed,
mice expressing about 50% of the rhodopsin levels observed in
wild-type mice, showed a clear reduction in rod function,
decreased length of photoreceptor outer segments at P15, and
thinning of the outer nuclear layer by one to two rows at P90 [Lem
et al., 1999]. On the other hand, the surprising observation that
the p.G56R mutant protein increased the repression of both S-
and M-opsin genes in the heterologous transactivation assays, was
different from in vivo data, where S-opsin mRNA expression was
derepressed in rd7/rd7 mice, but not that of M-opsin mRNA
expression [Chen et al., 2005; Corbo and Cepko, 2005].
Alternatively, the increase of S- and M-opsin repression by the
p.G56R mutant protein could be attributed to inhibition of an
activator protein. The competition between DNA-binding and
activator-binding existing for the NR2E3 wild-type protein would
then be shifted solely toward activator-binding for the p.G56R
mutant protein, resulting in a drop of promoter activity. With
respect to this latter potential mechanism, it will be interesting to
determine if the p.G56R mutation alters physical interactions with
the transcriptional activator CRX [Peng et al., 2005].
Impaired Corepressor-Binding by the ESCS-Linked NR2E3-
p.R311Q Mutant Protein
Individuals carrying the ESCS-causing p.R311Q mutation at a
heterozygous state did not show any clinical phenotype [Haider
et al., 2000]. But a beneficial effect of this mutation was uncovered
in the compound heterozygous patients of the American family, in
whom it cosegregated with the adRP-causing p.G56R mutation.
Strikingly, the ERG of the proband, Patient II-1, remained
stationary for 25 years with a classical ESCS phenotype. This also
indicated that the p.R311Q mutation was functionally dominant
to the p.G56R mutation.
The heterologous transactivation assays clearly showed that the
p.R311Q mutant protein failed to repress the M-opsin promoter
in presence of atrophin corepressors, suggesting that impaired
corepressor-binding was the molecular basis of ESCS. A beneficial
effect of the recessive p.R311Q mutation in presence of the
dominant p.G56R mutation, might therefore be due to increased
photoreceptor-specific gene expression caused by impaired
repression. As ligands for NR2E3 are not yet available [Wolken-
berg et al., 2006], we could not test: 1) if the p.R311Q mutation
altered the specificity and the affinity toward endogenous ligands
and the altered ligand binding caused corepressor release; 2) if the
p.R311Q mutation induced a subtle conformational change in the
LBD, permitting a corepressor/coactivator exchange; and, 3) if
corepressors were bound to unliganded and/or ligand-bound
NR2E3. It has to be mentioned that the p.R311Q mutation is
located outside the atrophin-binding region identified for NR2E1
[Wang et al., 2006; Zhang et al., 2006]. Consistently, in
transactivation assays in Y79 human retinoblastoma cells, the
corepressor Ret-CoR, structurally unrelated to atrophins, also
failed to repress the cyclin D1 promoter in the presence of the
p.R311Q mutant protein [Takezawa et al., 2007]. These results also
showed that NR2E3 repressive activity might be mediated by
distinct corepressor complexes, namely during development and
in the adult retina.
Whatever the exact molecular mechanisms mediated by the
p.R311Q mutation are, they cannot alone explain the
clinical differences observed in the proband, Patient II-1, and
her sister, Patient II-3. Modifier effects of unknown (or not
tested) genes and/or environmental influences are likely to be
involved. Interestingly, an extensive variability in ESCS
disease expression has been described in patients with homo-
zygous p.R311Q mutations; e.g., abundance of clumped retinal
pigments and rates of retinal degeneration [Audo et al., 2008;
Chavala et al., 2005; Gerber et al., 2000; Haider et al., 2000;
Hayashi et al., 2005; Milam et al., 2002; Sharon et al., 2003; Wright
et al., 2004]. Our observation that atrophins had to be
overexpressed in cell-based transactivation assays to see an effect
of the p.R311Q mutation on transactivation of target genes
suggests that corepressor levels could contribute to these clinical
differences in p.R311Q/p.G56R compound heterozygotes and in
p.R311Q/p.R311Q homozygotes.
In conclusion, and based on our experimental data, loss of
interaction with a corepressor is a plausible model for how the
p.R311Q mutant protein causes ESCS. Understanding the exact
mode of action of the p.R311Q mutant protein may open the
provocative perspective of introducing by gene therapy the mutant
p.R311Q protein in adRP patients carrying the p.G56R mutation,
to slow down the progression of adRP.
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